Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma 2017 Jul;58(7):1648-1654
Date
11/25/2016Pubmed ID
27881041DOI
10.1080/10428194.2016.1258700Scopus ID
2-s2.0-84996938114 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Chronic myelomonocytic leukemia (CMML) is an aggressive neoplasm with sparse data on outcomes at a population level. Using Surveillance Epidemiology and End Results (SEER) database, we identified 2238 patients with CMML diagnosed in the period 2003-2013. We found that the disease incidence was significantly higher with advancing age and lower in females, Blacks, and Asian/pacific islanders. Median OS declined significantly with increasing age (age 20-39 - 25 months, age 40-59 - 20 months, age 60-79 - 18 months, and age ≥80 - 11 months, p < .01), but did not vary by gender or race. Median OS has improved in the period 2007-2013 as compared with 2003-2006 (17 months vs. 14 months, p < .01). In spite of advances in CMML biology and therapeutics, in general, the survival of CMML patients remains dismal. More effective therapies are needed to improve the outcomes of CMML.
Author List
Guru Murthy GS, Dhakal I, Mehta PAuthor
Guru Subramanian Guru Murthy MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Female
Humans
Incidence
Leukemia, Myelomonocytic, Chronic
Male
Middle Aged
Patient Outcome Assessment
Population Surveillance
Prognosis
SEER Program
Survival Analysis
United States
Young Adult